Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Side effects in immunosuppressive therapy].

N Thumb

    Acta Medica Austriaca
    |January 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Immunosuppressive therapy for rheumatoid arthritis showed good results in 50% of patients. While potent drugs like procarbazine had side effects, the risk of malignancy appeared low, especially compared to kidney transplant patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Löfgren syndrome].

    Wiener medizinische Wochenschrift (1946)·2000
    Same author

    Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis.

    Clinical rheumatology·1995
    Same author

    [Drug therapy of arthrosis].

    Wiener medizinische Wochenschrift (1946)·1995
    Same author

    [Function of cytokines in cartilage degradation].

    Wiener medizinische Wochenschrift (1946)·1995
    Same author

    Bronchoalveolar lavage in rheumatoid arthritis.

    British journal of rheumatology·1993
    Same author

    [Helicobacter pylori and nonsteroidal antirheumatics].

    Deutsche medizinische Wochenschrift (1946)·1990
    Same journal

    [Gestational diabetes mellitus].

    Acta medica Austriaca·2005
    Same journal

    [Diagnosis, therapy and follow-up of diabetic eye diseases].

    Acta medica Austriaca·2005
    Same journal

    [Diabetic nephropathy].

    Acta medica Austriaca·2005
    Same journal

    [The diabetic foot].

    Acta medica Austriaca·2005
    Same journal

    [Diabetic neuropathy].

    Acta medica Austriaca·2005
    Same journal

    [Inhibition of platelet aggregation].

    Acta medica Austriaca·2005
    See all related articles

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring effective treatment.
    • Immunosuppressive therapy is a key treatment modality for RA, but carries potential risks.
    • Evaluating the efficacy and safety of various immunosuppressive agents in RA is crucial.

    Purpose of the Study:

    • To assess the efficacy and side effect profiles of multiple immunosuppressive agents in rheumatoid arthritis patients.
    • To compare the outcomes and risks associated with different immunosuppressive drugs used in RA treatment.

    Main Methods:

    • A cohort of 61 rheumatoid arthritis patients received 80 courses of immunosuppressive therapy.
    • Drugs administered included azathioprine, chlorambucil, mannitolmustard, cyclophosphamide, and procarbazine.

    Related Experiment Videos

  • Patients were monitored for treatment efficacy and adverse events, including short-term and long-term risks like malignancy.

    • Main Results:

    • Overall, 50% of patients experienced excellent or good treatment outcomes.
    • A significant correlation was observed between drug efficacy and the incidence of side effects.
    • Azathioprine was well-tolerated but yielded moderate results, while procarbazine showed higher efficacy but also more severe side effects (e.g., bone marrow depression, infections).
    • Serious immediate side effects included infections and leucopenia. No malignancies were detected in the up to five-year follow-up period.

    Conclusions:

    • Immunosuppressive therapy can be effective in managing rheumatoid arthritis, with half of patients achieving significant benefit.
    • Drug selection involves balancing efficacy against side effect profiles, with agents like procarbazine being potent but associated with higher risks.
    • The long-term risk of malignancy from immunosuppressive therapy in RA appears relatively low, contrasting with findings in other patient populations like kidney transplant recipients.